Eli Lilly (LLY)
(Delayed Data from NYSE)
$806.14 USD
-12.79 (-1.56%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$806.14 USD
-12.79 (-1.56%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
QIAGEN (QGEN) Q1 Earnings Lag Estimates, Operating Margin Up
by Zacks Equity Research
QIAGEN (QGEN) registered robust revenue growth across all geographies and each of its operating segments in Q1 despite the coronavirus-led economic crisis.
AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter earnings benefit from segmental growth.
Bio-Rad (BIO) Beats Q1 Earnings Estimates, Withdraws View
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter 2020 results reflect strong segmental performance boosted by coronavirus-led increased testing demand.
Exact Sciences' (EXAS) Q1 Earnings Fall Y/Y, Margin Expands
by Zacks Equity Research
Exact Sciences' (EXAS) first-quarter 2020 results reflect strong performance by Screening segment amid the coronavirus-led economic crisis.
Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.
Becton Dickinson (BDX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Becton Dickinson's (BDX) second-quarter results reflect solid performance by the core Life Sciences and Interventional segments.
Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View
by Zacks Equity Research
Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.
CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate
by Zacks Equity Research
Within CVS Health's (CVS) Retail/LTC, the coronavirus pandemic results in greater use of 90-day prescriptions and early refills of maintenance medications in the quarter.
Jazz Pharma (JAZZ) Misses on Q1 Earnings & Sales, Cuts View
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports lower-than-expected first-quarter 2020 earnings and revenues. It lowers its guidance for 2020. Shares drop.
Haemonetics (HAE) Q4 Earnings Lag Estimates, Margins Expand
by Zacks Equity Research
Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.
Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen (INGN) reported growth in business-to-business international and domestic revenues in Q1.
DaVita (DVA) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
DaVita's (DVA) dialysis services in the United States showcased solid results in Q1.
Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin
by Zacks Equity Research
Cardiovascular Systems (CSII) witnesses a significant decline in procedure volumes in Q3 for patients treated with orbital atherectomy devices.
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from growth in Discover & Analytics Solutions segment. However, forex remains a woe.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues
by Zacks Equity Research
Incyte (INCY) misses on first-quarter earnings due to an upfront payment made in March related to a collaboration agreement. Sales beat on strong Jakafi growth.
Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Henry Schein (HSIC) sees dismal performance by Dental arm in Q1 due to disruptions resulting from the coronavirus pandemic.
Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.
Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Teleflex's (TFX) first-quarter 2020 results reflect sales growth across few major segments despite the coronavirus pandemic.
Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) benefits from increased product demand due to the coronavirus outbreak.
Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down
by Zacks Equity Research
The coronavirus impact results in inaccessibility of several of Syneos Health's (SYNH) clinical trial sites.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View
by Zacks Equity Research
Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.
Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View
by Zacks Equity Research
Hologic (HOLX) exhibits robust segmental growth in second-quarter fiscal 2020, fueled by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
by Ritujay Ghosh
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.